3rd Annual Global Drug Bioavailability Enhancement Summit Event Summary Most drugs on today s market display poor solubility, but the use of modern solubilization technologies can improve a drug product s bioavailability and performance. Even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it is bioavailable. However, finding the ideal solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms. Additionally, biopharmaceutical firms hoping to develop oral delivery alternatives for biologics will also need to work out how to maximize the bioavailability, safety and effectiveness of their products. Small-and largemolecule therapeutics urgently need to overcome drug formulation and delivery challenges in order to improve bioavailability and therapeutic performance. Back by popular demand, the 3rd Annual Global Drug Bioavailability Enhancement Summit will be providing a holistic overview to bioavailability enhancements. We will be covering everything from large molecules to small molecules; oral drugs and parenterals (including nasal, pulmonary, transdermal, microneedles, ocular and more); as well as will be bridging the gap from early to late stage discovery and development. Throughout the program we will be bringing real-world stories and case-studies and covering the sessions and topics with best practices and lessons learned in interesting and interactive sessions, panels and roundtables instead of the standard, mundane traditional-style presentations. In addition, the 3rd Annual Global Drug Bioavailability Enhancement Summit strives to provide you unique and interesting solutions that can assist you and others on your team. We know that prediction and modeling tools and technologies; the move to continuous manufacturing; manners and methods to utilizing data; and legal, regulatory solutions amongst others are important to your role and company. And, our goal is to make sure we can provide you a wide array of ideas, tools, technologies, perspectives and thoughts to make your job easier. This event will truly provide to you and your colleagues great ideas and perspectives to share and further improve your strategies to bring novel formulations to-market more quickly. New for 2019: This event is co-located with the 3rd Annual Oral Drug Formulation Innovations Summit. Attendees and sponsors have access to this event as a value add. Who Should Attend Pharmaceutical, biotech and medical device professionals responsible for: Formulation/Preformulation Solubility/Solubilization Pharmaceutics/Biopharmaceutics Pharmacokinetics/Pharmacodynamics/ DMPK Manufacturing CMC Drug Delivery Medicinal Chemistry Preclinical Development Analytical Development Material Science Regulatory Affairs Toxicology
Physicochemistry Process R&D This Program Will Also Be of Interest to: Solubility and Formulation Service Providers Drug Delivery Service Providers API Manufacturers CROs CMOs Description Most drugs on today s market display poor solubility, but the use of modern solubilization technologies can improve a drug product's bioavailability and performance. Even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it is bioavailable. Most of the drugs and APIs currently on the market are poorly water-soluble and need to have their bioavailability improved through the development of enabled formulations and patient-centric delivery mechanisms. Finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms. Additionally, biopharmaceutical firms hoping to develop oral delivery alternatives for injectable biologics will also need to work out how to ensure that their products are bioavailable, safe and effective. Small-and large-molecule therapeutics urgently need to overcome drug formulation and delivery challenges in order to improve bioavailability and therapeutic performance. Curtis & Coulter s 3rd Annual Global Drug Bioavailability Enhancement Summit will examine and showcase the industry s latest formulation and delivery technologies for enhancing solubility and maximizing bioavailability. Learn directly from leading global formulation experts in both industry and academia on how to effectively develop poorly soluble drugs into scientifically unique, compliant, patient-centric formulations. Additionally, learn innovative strategies to significantly reduce product development timelines, brush up on the latest regulatory requirements and learn multiple innovative strategies to optimize and enhance your product portfolio. Please note the 3rd Global Drug Bioavailability Enhancement Summit is co-located with the 3rd Oral Drug Formulation Innovations Summit. Attendees have access to BOTH events as a value add. Advisory Board
James Ormes Associate Principal Scientist, Merck & Co., Inc. Haruki Hasegawa Principal Scientist, Amgen Inc. Madhavi Srikoti Research Scientist, Bristol-Myers Squibb Company Keith Horspool Vice President, Boehringer Ingelheim Pharmaceuticals Inc.
Eric Munson Professor, University of Kentucky Liping Zhou Senior Scientist, Ipsen Biosciences Robert K. Prud'homme Professor and Director Program in Engr. Biology, Princeton University
Esmaiel Jabbari Professor, Chemical Engineering, Biomedical Engineering, University of South Carolina Please contact the event manager Marilyn (marilyn.b.turner@nyeventslist.com ) below for: - Multiple participant discounts - Price quotations or visa invitation letters - Payment by alternate channels (PayPal, check, Western Union, wire transfers etc) - Event sponsorships NO REFUNDS ALLOWED ON REGISTRATIONS Service fees included in this listing. ----------------------------------------------------------------- Curtis & Coulter LLC. - New York Events List http://www.nyeventslist.com http://www.bostoneventslist.com http://www.sfbayeventslist.com ----------------------------------------------------------------- JOA190516CEV